Platelet Dysfunction
Conditions
Keywords
dapagliflozin, SGLT2i
Brief summary
Sodium GLucose Transport 2 inhibitors (SGLT2I), including dapagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated. The mechanistic effects of dapagliflozin on platelet function profiles have not yet been ascertained. It remains unclear if this reduction in cardiovascular death is mediated by decreased platelet reactivity.
Detailed description
Diabetes is highly prevalent in our setting. Dapagliflozin is now considered first-line treatment for diabetes, especially in the cardiovascular arena. The standard prescribed dosages of dapagliflozin will be employed in the research study (5 or 10 mg once daily). The reason the study team is interested in performing this study in our local setting is that if dapagliflozin does show a beneficial effect with either diabetic control or an antiplatelet effect, the team can then inform the Ministry of Health to acquire these relatively expensive medications in place of the older, less effective anti-diabetic drugs. The team has to demonstrate that they work effectively and safely in our population before approaching regulatory bodies with a robust recommendation that they are made available in the public healthcare sector. The patients that are to be selected will be relatively controlled on their current regimen, and thus not miss out on these medications after the study has been concluded as they are all available on the chronic disease assistance program (CDAP) such as metformin, gliclazide and insulin therapies. The study will aim to determine if dapagliflozin does demonstrate other latent antiplatelet effects that can potentially affect the cardiovascular/hematologic systems that have not investigated before.
Interventions
DRUGDAPA Tx
The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
Sponsors
The University of The West Indies
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study will be of a prospective, open-label trial design over a 2-year period. Patients at the Eric Williams Medical Sciences Complex (EWMSC), Mt. Hope, Trinidad and Tobago will be screened for potential eligibility.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. between 18 and 74 years of age, 2. have stable coronary artery disease and diabetes mellitus, already on DAPT with aspirin and clopidogrel for at least 6 months, 3. not on any physician-prescribed medications or complementary/alternative therapies.
Exclusion criteria
1. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding, 2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm, 3. history of clinical and/or hemodynamic instability, 4. within 1 month of placement of a bare-metal stent, 5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed, 6. planned coronary revascularization, 7. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h, 8. use of an oral anticoagulation agent or international normalized ratio \>1.5, 9. body weight \<60 kg, 10. age \>75 years, 11. hemoglobin \<10 g/dL, 12. platelet count \<100×106/μL, 13. creatinine \>2 mg/dL, 14. hepatic enzymes \>2.5 times the upper limit of normal, 15. pregnancy and/or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx | Baseline (0 weeks) to Completion (2 weeks) after Dapagliflozin | Platelet Reaction units at baseline and post-DAPA Tx treatment with dapagliflozin |
Countries
Trinidad and Tobago
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| DAPA Tx This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
DAPA Tx: The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks. | 27 |
| Total | 27 |
Baseline characteristics
| Characteristic | DAPA Tx |
|---|---|
| Age, Continuous | 63.5 years STANDARD_DEVIATION 1 |
| PRU | 160.93 PRU STANDARD_DEVIATION 1 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 20 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 40 |
| other Total, other adverse events | 0 / 40 |
| serious Total, serious adverse events | 0 / 40 |
Outcome results
Primary
Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx
Platelet Reaction units at baseline and post-DAPA Tx treatment with dapagliflozin
Time frame: Baseline (0 weeks) to Completion (2 weeks) after Dapagliflozin
| Arm | Measure | Value (MEAN) |
|---|---|---|
| DAPA Tx | Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx | 160.93 PRU |